Sign in
4

Changes in Ownership

Allogene Therapeutics, Inc. Filed Acc 0001209191-18-055372

Director bought 35,000 shares at $18.00 ($630,000)

  • Director acquired 7,628,936 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Belldegrun Arie Director 2018-10-15 Purchase +35,000 $18.00 $630,000 35,000 D: show line 1 in the form
Belldegrun Arie Director 2018-10-15 Conversion +142,248 3,710,006 I: show line 2 in the form
Belldegrun Arie Director 2018-10-15 Conversion +5,989,352 5,989,352 I: show line 3 in the form
Belldegrun Arie Director 2018-10-15 Conversion +1,497,336 1,497,336 I: show line 4 in the form
Open-market purchases · 35,000 sh · avg $18.00 · $630,000

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Belldegrun Arie Director 2018-10-15 Conversion · Series A Convertible Preferred Stock −27,095 0 I: show line 5 in the form
Belldegrun Arie Director 2018-10-15 Conversion · Series A Convertible Preferred Stock −1,140,829 0 I: show line 6 in the form
Belldegrun Arie Director 2018-10-15 Conversion · Series A Convertible Preferred Stock −285,207 0 I: show line 7 in the form
Loading xslF345X03/doc4.xml…